For the quarter ending 2026-03-31, AXSM made $191,203K in revenue. -$64,542K in net income. Net profit margin of -33.76%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 191,203 | 195,999 | 170,992 | 150,042 |
| Cost of revenue (excluding amortization and depreciation) | 14,725 | 12,329 | 11,912 | 13,448 |
| Research and development | 52,677 | 48,791 | 40,162 | 49,541 |
| Selling, general and administrative | 184,996 | 169,297 | 150,235 | 130,280 |
| Loss in fair value of contingent consideration | 590 | -9,068 | 13,185 | -8,102 |
| Intangible asset amortization | 1,572 | 1,607 | 1,607 | 1,589 |
| Total operating expenses | 254,560 | 222,956 | 217,101 | 186,756 |
| Loss from operations | -63,357 | -26,957 | -46,109 | -36,714 |
| Interest expense, net | -1,185 | -1,172 | -1,120 | -1,834 |
| Gain on debt extinguishment | - | 0 | - | -10,385 |
| Loss before income taxes | -64,542 | -28,129 | -47,229 | -48,933 |
| Income tax benefit | - | - | - | -960 |
| Income tax expense | 0 | 430 | - | -1,000 |
| Net loss | -64,542 | -28,559 | -47,229 | -47,973 |
| Basic EPS | -1.26 | -0.564 | -0.94 | -0.97 |
| Diluted EPS | -1.26 | -0.564 | -0.94 | -0.97 |
| Basic Average Shares | 51,198,349 | 50,653,697 | 50,021,851 | 49,442,001 |
| Diluted Average Shares | 51,198,349 | 50,653,697 | 50,021,851 | 49,442,001 |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)